Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis.
about
Quality of Life and Its Determinants in Adult Cancer Patients Undergoing Chemotherapy Treatment in PakistanThe risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.Neutropenic fever rates with adjuvant docetaxel and cyclophosphamide in early breast cancer: audit from regional cancer centre in New South Wales.
P2860
Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Febrile neutropenia rates with ...... practice-an updated analysis.
@ast
Febrile neutropenia rates with ...... practice-an updated analysis.
@en
type
label
Febrile neutropenia rates with ...... practice-an updated analysis.
@ast
Febrile neutropenia rates with ...... practice-an updated analysis.
@en
prefLabel
Febrile neutropenia rates with ...... practice-an updated analysis.
@ast
Febrile neutropenia rates with ...... practice-an updated analysis.
@en
P2093
P2860
P356
P1433
P1476
Febrile neutropenia rates with ...... practice-an updated analysis.
@en
P2093
P2860
P304
P356
10.3747/CO.19.1174
P577
2012-12-01T00:00:00Z